Biomunex Pharmaceuticals
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
113 Rue De La Tour, Paris, Ile-de-France...Website
www.biomunex.comRevenue
$6.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Biomunex Pharmaceuticals
Biomunex Pharmaceuticals is a Paris-based biopharmaceutical company specializing in the discovery and development of innovative immuno-therapeutics for oncology. The company utilizes its proprietary BiXAb technology to create bi- and multi-specific antibodies aimed at addressing unmet medical needs in cancer treatment. Biomunex is particularly focused on developing BiXAb-MAIT engagers that redirect MAIT cells to target and kill cancer cells, offering a promising alternative to existing therapies. Their commitment is to provide oncologists and patients with effective immunotherapies that enhance treatment outcomes and prolong life expectancy.Explore more
Biomunex Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biomunex Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Biomunex Pharmaceuticals has new funding data
Check out if Biomunex Pharmaceuticals is spiking on competitors!
Check if Biomunex Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Biomunex Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Biomunex Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Biomunex Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Biomunex Pharmaceuticals
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Biomunex Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Biomunex Pharmaceuticals as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Biomunex Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Biomunex Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Biomunex Pharmaceuticals.
Biomunex Pharmaceuticals Tech Stack
A closer look at the technologies used by Biomunex Pharmaceuticals
See more technologies
Biomunex Pharmaceuticals News & Media
Biomunex Signs Exclusive Licensing Agreement With Institut Curie to Develop MAIT Engagers, a New Class of Bispecific Antibodies in Immuno-oncology
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biomunex Pharmaceuticals, a French biopharmaceutical company specialized in the development of cutting-edge therapies through the discovery and development of bi- and multi-specific antibodies for the treatment of cancer, announced today the signature of an exclusive license and exploitation agreement with Institut Curie. This agreement covers the development of a new class of antibodies, capable of specifically targeting and engaging MAIT cells to kilBiomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biomunex Pharmaceuticals (Biomunex), a French biopharmaceutical company that develops cutting-edge immunotherapies through the discovery and development of bi- and multi-specific antibodies, generated from the BiXAb platform, for the treatment of cancer, announced today the enrollment in 2023 of the first patient in a Phase 1 clinical trial conducted by Onward Therapeutics SA (Onward Therapeutics). In preclinical studies, this antibody generated from BBiomunex Pharmaceuticals, a French Company Specialized in Immunotherapy, Presents the Latest Preclinical Results on Its Disruptive MAIT Cell Redirection Approach For Cancer Treatment at the 2023 AACR Annual Meeting
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biomunex Pharmaceuticals, a French biopharmaceutical company focused on the development of immunotherapies based on the discovery and development of bi- and multi-specific antibodies for the treatment of cancer, announced today that it will participate in and present new scientific data at the American Association for Cancer Research (AACR) annual meeting, which will take place from April 14th to April 19th, 2023 at the Orange County Convention Center,Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology
LAUSANNE, Switzerland, Feb. 16, 2021 /PR Newswire/ -- Onward Therapeutics SA (Onward) announced today the execution of a worldwide exclusive license and co-development agreement with Biomunex Pharmaceuticals SAS (Biomunex), Paris, France, of a bispecific antibody targeting two immune...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biomunex Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Biomunex Pharmaceuticals is a Paris-based biopharmaceutical company specializing in the discovery and development of innovative immuno-therapeutics for oncology. The company utilizes its proprietary BiXAb technology to create bi- and multi-specific antibodies aimed at addressing unmet medical needs in cancer treatment. Biomunex is particularly focu... Read More
